Articles by Roy Beveridge, MD
Future Directions of BTK Inhibitors in Leukemia and Lymphoma
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD Experts discuss future directions of BTK inhibitors.
Patient Access Advocacy for BTK Inhibitors
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A panel of specialists discuss patient access advocacy for BTK inhibitors.
The Inflation Reduction Act: Implications for Patient Access in CL
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A group of experts discuss implications for patient access in CLL.
Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A panel of experts discuss navigating access challenges in CLL treatment.
Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD Experts discuss financial challenges of BTK inhibitor therapy.
Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A panel of experts discuss combination regimens with BTK inhibitors.
Decision-Making in CLL: The Role of Real-World Evidence
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A discussion on therapeutic decision-making in CLL and the role of real-world evidence.
Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.
Optimizing Therapy Sequencing in CLL
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A panel of experts discuss optimizing therapy sequencing in CLL.
Empowering Patients: Key Considerations for BTK Inhibitor Adherence
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A conversation on how to empower patients and the considerations for BTK inhibitor adherence.
Factors Influencing Choice of Second-Generation BTKi Monotherapy
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD Specialists discuss factors influencing the choices of second-generation BTK monotherapy.
Evaluating Value of BTK Inhibitors in CLL Treatment
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD Experts evaluate the value of BTK inhibitors in CLL treatment.
CLL Treatment Landscape: Overview of BTK Inhibitors
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.
Recent Trends and Innovations in the Management of CLL
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.
Cost Differential by Site of Service for Cancer Patients Receiving Chemotherapy
ByJad Hayes, MS, ASA, MAAA,J. Russell Hoverman, MD, PhD,Matthew E. Brow, BA,Dana C. Dilbeck, BA,Diana K. Verrilli, MS,Jody Garey, PharmD,Janet L. Espirito, PharmD,Jorge Cardona, BS,Roy Beveridge, MD The cost of care for patients receiving chemotherapy in community oncology clinics is lower than for comparable patients receiving chemotherapy in the hospital outpatient setting.